Condition: Psoriasis · Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.
This description comes directly from the study's public registry record.
Bingjing Feng · +86 18361923769 · bingjing.feng@innoventbio.com
Always discuss trial participation with your own doctor first.
| Beijing Children's Hospital Affiliated to Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07265284